NewGenIvf Group Limited (NASDAQ:NIVF – Get Free Report) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 91,719 shares, a drop of 46.6% from the August 15th total of 171,641 shares. Currently, 6.4% of the shares of the stock are short sold. Based on an average trading volume of 672,683 shares, the short-interest ratio is currently 0.1 days.
Insider Transactions at NewGenIvf Group
In other news, Director Kong Yiu Cheung acquired 2,500,000 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were acquired at an average cost of $1.00 per share, with a total value of $2,500,000.00. Following the completion of the purchase, the director directly owned 3,722,223 shares of the company’s stock, valued at $3,722,223. The trade was a 204.55% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 31.80% of the stock is owned by company insiders.
NewGenIvf Group Stock Down 6.6%
Shares of NewGenIvf Group stock traded down $0.06 during midday trading on Wednesday, hitting $0.78. 141,504 shares of the company traded hands, compared to its average volume of 110,937. The company has a current ratio of 3.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.16. The firm’s fifty day moving average price is $2.17 and its 200-day moving average price is $9.17. NewGenIvf Group has a 12 month low of $0.71 and a 12 month high of $1,539.00.
Analysts Set New Price Targets
View Our Latest Research Report on NIVF
NewGenIvf Group Company Profile
NewGenIVF Group Inc, trading on NASDAQ under the symbol NIVF, is an integrated provider of reproductive medicine services in the People’s Republic of China. The company operates a network of fertility clinics across major Chinese cities, delivering comprehensive infertility diagnosis and treatment to patients and couples. Its facilities are equipped with modern laboratories and surgical suites designed for assisted reproductive procedures.
NewGenIVF’s service offerings encompass a wide range of assisted reproductive technologies (ART), including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and fertility preservation through ovarian tissue and gamete cryopreservation.
See Also
- Five stocks we like better than NewGenIvf Group
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for NewGenIvf Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewGenIvf Group and related companies with MarketBeat.com's FREE daily email newsletter.
